CHMP recommends Signifor to treat Acromegaly - Novartis
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Signifor (pasireotide) long acting release (LAR) formulation from Novartis, to treat adult patients with Acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue (SSA).
If approved in the EU, this next-generation SSA could fill a current unmet need, providing a new therapeutic option for the approximately 45% of acromegaly patients whose growth hormone (GH) or insulin-like growth factor-1 (IGF-1) levels remain inadequately controlled despite treatment with currently available somatostatin analogues.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins